Andrew Reardon - 14 Feb 2025 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
CLO & Secretary
Signature
/s/ Andrew Reardon
Issuer symbol
LGND
Transactions as of
14 Feb 2025
Net transactions value
-$782,760
Form type
4
Filing time
19 Feb 2025, 20:37:29 UTC
Previous filing
25 Sep 2024
Next filing
06 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Award $0 +6,928 +31% $0.000000 29,462 14 Feb 2025 Direct F1
transaction LGND Common Stock Tax liability $333,000 -2,775 -9.4% $120.00 26,687 14 Feb 2025 Direct F2
transaction LGND Common Stock Award $0 +5,429 +20% $0.000000 32,116 14 Feb 2025 Direct F1
transaction LGND Common Stock Tax liability $210,960 -1,758 -5.5% $120.00 30,358 14 Feb 2025 Direct F2
transaction LGND Common Stock Tax liability $133,680 -1,114 -3.7% $120.00 29,244 15 Feb 2025 Direct F3
transaction LGND Common Stock Tax liability $105,120 -876 -3% $120.00 28,368 15 Feb 2025 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock issued upon the vesting and certification of performance stock units (PSUs).
F2 Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of performance stock units.
F3 Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units.